Trulicity (Dulaglutide) Safety Signals and FDA Actions

How Dulaglutide Works: Mechanism Behind the Safety Profile

Dulaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics endogenous GLP-1 to stimulate glucose-dependent insulin secretion, suppress glucagon release, and slow gastric emptying. Understanding this mechanism matters because most of Trulicity's safety signals trace directly back to GLP-1 receptor activity in specific tissues.

The molecule consists of two GLP-1 analogue peptides covalently linked to a modified human immunoglobulin G4 (IgG4) Fc fragment. This design extends the half-life to approximately 5 days, allowing once-weekly dosing 1. GLP-1 receptors are distributed across multiple organ systems, including the pancreas, gastrointestinal tract, kidneys, heart, and thyroid C-cells. The presence of these receptors in thyroid tissue is the biological basis for the boxed warning on all GLP-1 receptor agonists.

Glucose-dependent insulin secretion means the drug primarily drives insulin release when blood glucose is elevated. This feature reduces hypoglycemia risk compared to sulfonylureas or exogenous insulin, though the risk is not zero. When dulaglutide is layered onto insulin therapy, hypoglycemia rates increase meaningfully. In the AWARD-9 trial, 12.5% of patients on dulaglutide 1.5 mg plus insulin glargine experienced documented symptomatic hypoglycemia (<54 mg/dL) versus 8.9% on placebo plus glargine 2.

Slowed gastric emptying explains the most common side effects: nausea, vomiting, and diarrhea. These are not safety signals per se but contribute to early discontinuation in approximately 1.3% to 6.2% of patients across the AWARD clinical program 3.

The FDA Boxed Warning: Thyroid C-Cell Tumors

The most prominent regulatory action on Trulicity's label is the boxed warning for risk of thyroid C-cell tumors. This warning applies to the entire GLP-1 receptor agonist class and was established before dulaglutide's 2014 approval based on preclinical toxicology.

In rodent carcinogenicity studies, dulaglutide caused dose-dependent increases in thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), at exposures relevant to the human therapeutic dose 4. The FDA requires that the label state: "It is unknown whether Trulicity causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans." The warning contraindicates dulaglutide in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Rat thyroid C-cells express GLP-1 receptors at far higher density than human C-cells. That biological difference is relevant. A 2021 nested case-control study using the French national health insurance database (N=2,562 thyroid cancer cases) found no statistically significant association between GLP-1 receptor agonist use and medullary thyroid carcinoma (OR 1.30, 95% CI 0.35-4.88) 5. A separate large cohort study published in Diabetes Care involving over 145,000 GLP-1 receptor agonist users similarly found no increased thyroid cancer incidence over a median follow-up of 3.9 years 6.

The boxed warning remains. No human trial has been long enough or powered to definitively rule out a small absolute risk. Clinicians should document thyroid cancer history before prescribing and instruct patients to report neck masses, dysphagia, or persistent hoarseness.

Pancreatitis: Signal, Surveillance, and Clinical Reality

Acute pancreatitis was identified as a potential risk during the GLP-1 receptor agonist class review that began with exenatide in the late 2000s. For dulaglutide specifically, the FDA label lists acute pancreatitis as a warning and precaution.

Across the pooled AWARD clinical trial program, the incidence of adjudicated pancreatitis events was low: 5 cases (0.1%) in dulaglutide-treated patients versus 1 case (<0.1%) in comparator arms 3. The REWIND cardiovascular outcomes trial (N=9,901, median follow-up 5.4 years) provided the most strong long-term data. In REWIND, acute pancreatitis occurred in 24 patients (0.5%) on dulaglutide 1.5 mg versus 17 patients (0.3%) on placebo, a numerical difference that did not reach statistical significance 7.

The American Gastroenterological Association's 2024 clinical practice update advised that "a history of acute pancreatitis is not an absolute contraindication to GLP-1 receptor agonist therapy, provided the inciting cause has been addressed" 8. Standard clinical practice calls for baseline lipase measurement, discontinuation of dulaglutide if pancreatitis is suspected, and permanent avoidance if confirmed pancreatitis occurs on therapy.

Pancreatic cancer was also surveilled. REWIND reported 11 cases (0.2%) on dulaglutide versus 14 cases (0.3%) on placebo, providing no signal of increased pancreatic malignancy risk over 5.4 years 7.

Gallbladder Disease and Biliary Events

GLP-1 receptor agonists as a class increase the risk of gallbladder-related events. The mechanism likely involves altered gallbladder motility and bile composition from GLP-1 receptor activation on gallbladder smooth muscle.

In the REWIND trial, cholelithiasis occurred in 1.3% of dulaglutide-treated patients versus 1.0% in the placebo group. Cholecystitis rates were 0.6% versus 0.4%, respectively 7. These differences are small in absolute terms but consistent across GLP-1 receptor agonist trials. A 2022 meta-analysis of 76 randomized controlled trials involving GLP-1 receptor agonists found a pooled relative risk of 1.27 (95% CI 1.10-1.47) for gallbladder or biliary events compared with controls 9.

The FDA updated the Trulicity label to include acute cholecystitis among the adverse reactions identified during postmarketing use. Patients with pre-existing gallbladder disease should be monitored, and clinicians should consider the diagnosis when patients present with upper abdominal pain on therapy.

Cardiovascular Safety: REWIND and the MACE Endpoint

The REWIND trial was designed as an FDA-mandated cardiovascular outcomes trial. Unlike most GLP-1 receptor agonist cardiovascular trials at the time, REWIND enrolled a broader population: only 31% had established cardiovascular disease at baseline. The remaining participants had cardiovascular risk factors but no prior events.

Over a median 5.4 years, dulaglutide 1.5 mg reduced the composite MACE endpoint (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke) by 12% (HR 0.88, 95% CI 0.79-0.99; P=0.026) 7. The benefit was driven primarily by a reduction in nonfatal stroke (HR 0.76, 95% CI 0.61-0.95). Cardiovascular death (HR 0.91) and nonfatal MI (HR 0.96) showed directional benefit but did not individually reach significance.

Dr. Hertzel Gerstein, the REWIND principal investigator, noted in the Lancet publication: "These results extend the evidence for cardiovascular benefit of GLP-1 receptor agonists to a population with a broader range of cardiovascular risk" 7.

REWIND found no signal for heart failure hospitalization (HR 0.93, 95% CI 0.77-1.12), which alleviated earlier class-level concerns. Atrial fibrillation and flutter were reported numerically more often in the dulaglutide group (60 vs. 56 events), but this difference was not statistically significant and has not prompted FDA action 7.

Postmarketing Surveillance and Label Updates

Since Trulicity's September 2014 approval, the FDA has required several label revisions based on postmarketing adverse event reports.

Anaphylaxis and serious hypersensitivity reactions were added to the warnings and precautions section. The label now advises discontinuation of dulaglutide and prompt medical treatment if anaphylaxis or angioedema occurs 4. Injection site reactions, including injection site abscess, cellulitis, and necrosis, appeared in postmarketing reports, likely related to immunogenicity in a small subset of patients.

Anti-drug antibody (ADA) formation occurred in approximately 1.6% of patients across clinical trials. Of these, fewer than 1% developed neutralizing antibodies. No consistent pattern linked ADA positivity to reduced efficacy or increased adverse events in the AWARD program 4.

The FDA Adverse Event Reporting System (FAERS) has also logged reports of intestinal obstruction in patients on GLP-1 receptor agonists, though causality assessment is complicated by confounders such as gastroparesis in the type 2 diabetes population 10. The FDA issued a broad class-level review of gastrointestinal obstruction signals in 2023 and concluded that while monitoring was warranted, available data did not support a causal relationship specific to dulaglutide.

A 2023 population-based study using insurance claims data found that GLP-1 receptor agonist use was associated with an increased risk of pancreatitis (HR 1.9, 95% CI 1.6-2.3), intestinal obstruction (HR 4.2, 95% CI 3.1-5.7), and gastroparesis (HR 3.7, 95% CI 3.0-4.6) compared with bupropion-naltrexone, although these estimates were not specific to dulaglutide alone 10.

Renal Safety and Diabetic Kidney Disease

REWIND provided reassuring data on renal outcomes. The secondary renal composite endpoint (new macroalbuminuria, sustained 30% decline in eGFR, or chronic renal replacement therapy) occurred in 17.1% of the dulaglutide group versus 19.6% of the placebo group (HR 0.85, 95% CI 0.77-0.93; P=0.0004) 11.

This renal signal was primarily driven by a reduction in new-onset macroalbuminuria. Hard renal endpoints (sustained eGFR decline, dialysis) were too infrequent to detect differences. The REWIND investigators stated that "dulaglutide can be used with confidence in patients with moderate chronic kidney disease (eGFR 15-60 mL/min/1.73 m²)" based on the trial's prespecified subgroup analyses 11.

No dose adjustment is required for dulaglutide in patients with mild to moderate renal impairment (eGFR ≥15). The drug is not recommended in patients with severe renal impairment or end-stage renal disease due to limited clinical experience, not a documented safety signal 4.

Retinopathy Considerations

Unlike semaglutide, which showed an early worsening of diabetic retinopathy in the SUSTAIN-6 trial, dulaglutide has not demonstrated a retinopathy safety signal. In REWIND, retinal photocoagulation or treatment with an intravitreal agent occurred at similar rates in the dulaglutide and placebo groups 7. The Endocrine Society's 2024 clinical practice guideline on pharmacologic management of type 2 diabetes did not list retinopathy as a concern specific to dulaglutide, distinguishing it from higher-dose semaglutide 12.

This distinction is clinically useful in patients with active proliferative retinopathy or severe non-proliferative retinopathy where rapid HbA1c reduction may trigger retinal complications.

Trulicity Discontinuation and Market Context

Eli Lilly announced in 2024 that it would discontinue manufacturing Trulicity to redirect production capacity toward tirzepatide (Mounjaro/Zepbound). This was not an FDA-directed withdrawal for safety reasons. The safety profile of dulaglutide remains unchanged, and generic dulaglutide is not available as of 2026 due to existing patent protections.

Patients transitioning off Trulicity should work with their prescriber to select an alternative GLP-1 receptor agonist. The Endocrine Society guideline recommends semaglutide or tirzepatide as preferred agents for patients with type 2 diabetes and established cardiovascular disease, given their broader outcomes data and FDA indications 12.